Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | MLLT1 | Q03111 | 9/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | MLLT3 | P42568 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250334 | 0.74 | DNMT1 (0.46) | MAPK14MLLT1TGFBR1SCN5ADNMT1 | |
| SCHEMBL2736776 | 0.74 | DNMT1 (0.46) | MAPK14MLLT1TGFBR1SCN5ADNMT1 | |
| SCHEMBL252922 | 0.74 | PIK3CG (0.47) | MAPK14MLLT1TGFBR1SCN5ADNMT1 | |
| SCHEMBL21369473 | 0.74 | DNMT1 (0.46) | MAPK14MLLT1SCN5ADNMT1MLLT3 | |
| SCHEMBL24816112 | 0.74 | DNMT1 (0.46) | MAPK14MLLT1TGFBR1SCN5ADNMT1 | |
| SCHEMBL2538610 | 0.74 | SCN5A (0.51) | MAPK14MLLT1TGFBR1SCN5ADNMT1 | |
| SCHEMBL20600643 | 0.74 | DNMT1 (0.42) | MAPK14MLLT1TGFBR1SCN5ADNMT1 | |
| SCHEMBL20858664 | 0.74 | SCN5A (0.51) | MAPK14MLLT1TGFBR1SCN5ADNMT1 | |
| SCHEMBL23432690 | 0.72 | MLLT1 (0.49) | MAPK14MLLT1SCN5ADNMT1MLLT3 | |
| Hydrochloric Acid SCHEMBL22124466 | 0.72 | DNMT1 (0.45) | MAPK14MLLT1TGFBR1SCN5ADNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025044946-A1 | COMPOUND ACTING AS MRGPRX2 ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119504738-A | Compounds as MRGPRX2 antagonists, methods of preparation and use thereof | 武汉人福创新药物研发中心有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| EP-3004097-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2018-01-17 | — | — | EP | disclosed |
| EP-3004097-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2018-01-17 | — | — | EP | disclosed |
| EP-3004098-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-3004087-B1 | DERIVATIVES OF [1,2,4]TRIAZOLO[4,3-A]PYRIDINE AS P38-MAP KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-3004098-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-3004087-B1 | DERIVATIVES OF [1,2,4]TRIAZOLO[4,3-A]PYRIDINE AS P38-MAP KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-8907094-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-09 | — | — | US | disclosed |
| US-8907094-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-09 | — | — | US | disclosed |
| US-8907094-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-09 | — | — | US | disclosed |
| US-20140323470-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| US-20140323470-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| US-20140323470-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| WO-2013083206-A1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323470-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | MAPK14 33/4885MLLT1 1760/4885TGFBR1 463/4885 |
| US-20130150343-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | MAPK14 33/4885MLLT1 1760/4885TGFBR1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.